HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO CF PharmTech - The Outlook Is Bleak Due to VBP and Fierce Competition

Pre-IPO Bama Tea - The Business Model, the Challenges and the Outlook

Pre-IPO Fujian Lemo IoT Technology - The Outlook for Growth and Profit Margins Is Not Optimistic

Equity Capital Markets

Suzhou Ribo Life Science / Equity Capital Markets

<ul>
<li>The delivery system is a crucial element that drives the development/iteration of innovative oligonucleotide therapeutics. Ribo has mastered both GalNAc and LNP technologies, whose effectiveness/safety have been verified and recognized.</li>
<li>The valuation fluctuations not only reflect the market's prudence towards commercialization prospects of small nucleic acid drugs, but also highlight the balance problem between Ribo’s R&amp;D investment and profit model.</li>
<li>Since Sirnaomics’ delivery technologies have not been proven or validated scientifically, Ribo’s valuation should be higher than Sirnaomics.Valuation outlook is based on the druggability and commercialization performance of Ribo’s pipelines. </li>
</ul>


The delivery system is a crucial element that drives the development/iteration of innovative oligonucleotide therapeutics. Ribo has mastered both GalNAc and LNP technologies, whose effectiveness/safety have been verified and recognized.
The valuation fluctuations not only reflect the market's prudence towards commercialization prospects of small nucleic acid drugs, but also highlight the balance problem between Ribo’s R&amp;D investment and profit model.
Since Sirnaomics’ delivery technologies have not been proven or validated scientifically, Ribo’s valuation should be higher than Sirnaomics.Valuation outlook is based on the druggability and commercialization performance of Ribo’s pipelines. 


Pre-IPO Suzhou Ribo Life Science - The Strength, the Concerns and the Outlook for the SiRNA Unicorn